Movement Alert｜AKESO Falls 3.19% in Regular Trading, Biotech Sector Broadly Under Pressure After Third Indication Approval

Market Focus

Aug 14

On August 14, AKESO fell 3.19% in regular trading, trading at 100.4 HKD/share, with turnover of HKD 112 million.

Despite the company announcing on August 12 that its core product Ivonescimab (PD-1/VEGF bispecific antibody) received NMPA approval for its third indication — first-line treatment of advanced squamous non-small cell lung cancer in combination with chemotherapy — the stock failed to sustain gains and retreated amid broader sector weakness. The approval was based on positive results from the Phase III HARMONi-6 study comparing Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy.

The biotech sector was broadly under pressure on the day, with ZAI LAB down 4.51%, BEONE MEDICINES down 1.64%, REMEGEN down 1.33%, SKB BIO down 0.48%, and INNOVENT BIO down 0.42%. AKESO's decline exceeded the sector average, suggesting profit-taking pressure following the prior catalyst being priced in.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/news/1120959165"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1120959165\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1120959165?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-14 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1120959165","market":"hk","top_or_hot":-1,"title":"Movement Alert｜AKESO Falls 3.19% in Regular Trading, Biotech Sector Broadly Under Pressure After Third Indication Approval","media":"Market Focus","content":"<p><p>On August 14, AKESO fell 3.19% in regular trading, trading at 100.4 HKD/share, with turnover of HKD 112 million.</p><p>Despite the company announcing on August 12 that its core product Ivonescimab (PD-1/VEGF bispecific antibody) received NMPA approval for its third indication — first-line treatment of advanced squamous non-small cell lung cancer in combination with chemotherapy — the stock failed to sustain gains and retreated amid broader sector weakness. The approval was based on positive results from the Phase III HARMONi-6 study comparing Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy.</p><p>The biotech sector was broadly under pressure on the day, with ZAI LAB down 4.51%, BEONE MEDICINES down 1.64%, REMEGEN down 1.33%, SKB BIO down 0.48%, and INNOVENT BIO down 0.42%. AKESO's decline exceeded the sector average, suggesting profit-taking pressure following the prior catalyst being priced in.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜AKESO Falls 3.19% in Regular Trading, Biotech Sector Broadly Under Pressure After Third Indication Approval</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜AKESO Falls 3.19% in Regular Trading, Biotech Sector Broadly Under Pressure After Third Indication Approval\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-14 09:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 14, AKESO fell 3.19% in regular trading, trading at 100.4 HKD/share, with turnover of HKD 112 million.</p><p>Despite the company announcing on August 12 that its core product Ivonescimab (PD-1/VEGF bispecific antibody) received NMPA approval for its third indication — first-line treatment of advanced squamous non-small cell lung cancer in combination with chemotherapy — the stock failed to sustain gains and retreated amid broader sector weakness. The approval was based on positive results from the Phase III HARMONi-6 study comparing Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy.</p><p>The biotech sector was broadly under pressure on the day, with ZAI LAB down 4.51%, BEONE MEDICINES down 1.64%, REMEGEN down 1.33%, SKB BIO down 0.48%, and INNOVENT BIO down 0.42%. AKESO's decline exceeded the sector average, suggesting profit-taking pressure following the prior catalyst being priced in.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1120959165","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1120959165","pubTimestamp":1786671394,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 14, AKESO fell 3.19% in regular trading, trading at 100.4 HKD/share, with turnover of HKD 112 million.Despite the company announcing on August 12 that its core product Ivonescimab...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"走势警报|AKESO常规交易下跌3.19%，第三个适应症获批后生物技术板块普遍承压","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On August 14, AKESO fell 3.19% in regular trading, trading at 100.4 HKD/share, with turnover of HKD 112 million.Despite the company announcing on August 12 that its core product Ivonescimab (PD-1/VEGF bispecific antibody) received NMPA approval for its third indication — first-line treatment of advanced squamous non-small cell lung cancer in combination with chemotherapy — the stock failed to sustain gains and retreated amid broader sector weakness. The approval was based on positive results from the Phase III HARMONi-6 study comparing Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy.The biotech sector was broadly under pressure on the day, with ZAI LAB down 4.51%, BEONE MEDICINES down 1.64%, REMEGEN down 1.33%, SKB BIO down 0.48%, and INNOVENT BIO down 0.42%. AKESO's decline exceeded the sector average, suggesting profit-taking pressure following the prior catalyst being priced in.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}